1 / 36

Order Verification for High Risk Medications Review

Order Verification for High Risk Medications Review. August 17 th , 2017 Ashley Thompson, PharmD. Unfractionated Heparin Infusions. Contraindications and cautions Allergy to heparin or hypersensitivity to pork products History of Heparin Induced Thrombocytopenia (HIT)

Download Presentation

Order Verification for High Risk Medications Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Order Verification for High Risk MedicationsReview August 17th, 2017 Ashley Thompson, PharmD

  2. Unfractionated Heparin Infusions • Contraindications and cautions • Allergy to heparin or hypersensitivity to pork products • History of Heparin Induced Thrombocytopenia (HIT) • Active bleeding, where the risk of bleeding outweighs the benefit from thrombosis treatment or prevention • Use caution • IM injections and arterial punctures during anticoagulant therapy • Concurrent medications that affect platelet function (i.e. NSAIDs, Aspirin, Dipyridamole, Clopidogrel, etc.) • Use caution in patients with platelets <60

  3. Heparin Infusion Background • Therapeutic aPTT within 24 hours associated with reduced thromboembolism recurrence • Weight based heparin dosing associated with quicker time to therapeutic aPTT range • Limited data in obese patients • No consensus on dosing strategy • Data suggests using 100kg dose cap or adjusted weight Therapeutic aPTT 50-70.9sec Hull RD, et al. N Engl J Med 1986;15:1109–1114 Raschke R et al. Ann Intern Med 1993; 119:874-81.

  4. Summary of Recent Heparin Order-set updates • All heparin infusions in a single order set • Exc: EKOS • Weight based titration algorithm • Example: Increase/decrease by 1 unit/kg/hour instead of 100 units/hour • Weight cap of 100kg for obese patients • Pre-checked bolus, as appropriate • VAD protocol & Fixed dose added • Widespread effort to update Alaris infusion pumps more efficiently

  5. Recent Heparin Build Updates

  6. Why were these updates made?

  7. Compliance to Heparin Infusion Guideline dosing2014 MUE (N= 168 orders (114 patients)) NO BOLUS CI: 15 units/kg/hr Bolus: 60 units/kg CI: 12 units/kg/hr Bolus: 80 units/kg CI: 18 units/kg/hr

  8. Compliance to Heparin Infusion Guideline dosing2014 MUE (N= 168 orders (114 patients))

  9. Time to Therapeutic Goal (TTG)* 2014 MUE (N= 168 orders (114 patients) Olson J, Arkin C, Brandt J, Cunningham M.  Arch Pathol Lab Med. 1998;122:782-798.

  10. Heparin Quality Assurance Audit Results

  11. Post Heparin Implementation Updates • Use “drug dosing weight (admit weight)” for all patients  ≤100kg • Use “order-specific weight” in the heparin order for all patients > 100kg and enter 100kg Pharmacist Facing BPA Implemented Monday June 26th, 2017

  12. Unfractionated Heparin Monitoring with Anti-Xa Levels

  13. aPTT Monitoring for Systemic HeparinBackground • Activated partial thromboplastin time • Measures global activity of intrinsic coagulation factors targeted by heparin • Most widely used method for therapeutic monitoring of heparin • Therapeutic range for systemic heparin: 1.5 - 2.5x the control value Targets of heparin-antithrombin complex Eikelboom J. 2006. Francis et al. 2004

  14. aPTT Monitoring for Systemic HeparinConcerns • Preanalytic sampling issues: different aPTT reagents produce different reference ranges (1.6 - 2.7x to 3.7 - 6.2x control) • Patient-specific variables affect ability to achieve appropriate heparin dose and monitoring of aPTT Olson et al. 1998.

  15. Anti-Xa Monitoring for Systemic HeparinBackground • Measures ability of heparin-antithrombin complex to inhibit activated Factor X • Direct measure of heparin’s intrinsic activity on a single enzyme • Reference range: 0.3 - 0.7 anti-Xa units/mL • Not affected by patient-specific issues related to aPTT monitoring • Factor VIII or fibrinogen elevations associated with acute phase reactions • Other factor deficiencies associated with liver disease • Presence of antiphospholipid antibodies • No need for lab to create a reagent-specific reference range Lehman et al. 2009. Guervil et al. 2011. CHEST Antithrombotic Therapy and Prevention of Thrombosis, 9th ED: ACCP Guidelines, Parenteral Anticoagulants. 2012

  16. Brief Overview of Anti Xa Literature In summary, studies show similar efficacy with an improved safety profile

  17. Anti-Xa Availability at Other InstitutionsNational Survey Pharmacist list serve – 2016 (n=87) Available at ~75% of hospitals; Nursing-driven protocol – 31%

  18. Anti-Xa Availability at UCSF • Anti-Xa assay is available at UCSF • Test run 7 days per week, 0800 - 2300 • Turn-around time ~2 hours

  19. Current Anti-Xa Algorithm at UCSFMCExcludes ECLS/VAD Anti-Xa level to be checked q6hours until 2 consecutive therapeutic levels, then qAM

  20. Background Continuous Flow Left Ventricle Assist Devices • High rate of discordance between anti-factor Xa heparin assays & aPTT – 74.7% [supra therapeutic aPTTs, therapeutic anti Xa] • 96% Observed aPTT above expected range • Higher rates of discordance in patients with: • Higher INR values • Low levels of factor XII, V • Hemolysis (LDH) • 97% patients with elevated VIII • Patients at risk for thrombosis and gastrointestinal bleeding Adatya S et a. J Heart Lung Transplant 2016; 35: 1311-1320

  21. Anti-Xa at Other InstitutionsNational Survey Pharmacist list serve – 2017 (n=41)

  22. Anti-Xa at Other Institutions for MCS PatientsNational Survey Pharmacist list serve – 2017 (n=41) ECLS • Four institutions use ACT for monitoring ECLS • ECLS Goals (most have one range): • 0.3-0.5 (4) • 0.2-0.5 (2) • 0.3-0.7 (2) VAD PROTOCOLS • Low Intensity Targets • 0.2-0.4 (low) or 0.15-0.25 (ultra low) • 0.1-0.3 • 0.2-0.5 • Standard • 0.3-0.7 (3) • 0.2-0.5 (1) • High • 0.3-0.7 (2)

  23. Proposed LVAD Algorithm Adatya S et a. J Heart Lung Transplant 2016; 35: 1311-1320 Adatya S et a.. J Am CollCardiol HF 2015; 3:314-22

  24. Proposed Titration Algorithm • Recommended Provider Driven Titration Algorithm for LVAD patients • > 0.2 units/mL BELOW the target therapeutic range, INCREASE heparin infusion by 3 units/kg/hour • 0.1-0.19 units/mL BELOW the target therapeutic range, INCREASE heparin infusion by 2 units/kg/hour • 0.01 - 0.09 units/mL BELOW the target therapeutic range, INCREASE heparin infusion by 1 units/kg/hour • If within target therapeutic range, no adjustment needed • 0.01 - 0.09 units/mL above the target therapeutic range, DECREASE heparin infusion by 1 units/kg/hour • 0.1-0.19 units/mL ABOVE the target therapeutic range, DECREASE heparin infusion by 2 units/kg/hour • 0.2-0.29 units/mL ABOVE the target therapeutic range, DECREASE heparin infusion by 3 units/kg/hour • > 0.3 units/mL ABOVE the target therapeutic range, HOLD heparin for 60 minutes and DECREASE heparin infusion by 4 units/kg/hour Presentation Title and/or Sub Brand Name Here

  25. Helpful Anticoagulation References https://carelinks.ucsfmedicalcenter.org/ Presentation Title and/or Sub Brand Name Here

  26. What is wrong with this heparin order? • San Francisco, Sandy MRN: 58052647 • Orders, Teri MRN: MRN 58043141 • Clindoc Mekhala MR: 58047783 • Test William MRN: 58042641 • Wanttheflu, Donna MRN: 58050091 • Anticoagulation and Epidurals

  27. Parenteral Direct Thrombin Inhibitors • Patients with suspected/confirmed HIT are typically anticoagulated with a parenteral direct thrombin inhibitor, such as bivalirudin or argatroban. • Argatroban • hepatically eliminated • Bivalirudin • cleared by blood proteases (80%) and renal elimination (20%). • A copy of Stepwise Approach for Suspected Heparin-Induced Thrombocytopenia may be found on the pharmacy website

  28. Argatroban • Indications • treatment or prophylaxis of thrombosis with heparin-induced thrombocytopenia • Monitoring: • aPTT should be obtained q 2 hours after initiating drip until therapeutic, then q 4 hours until two consecutive values • Known to increase PT/INR lab values, use caution when bridging to Warfarin LinkinsLA, Dans AL, Moores LK, et al. Chest. 2012;141:e495S–530S Alquwaizani, Mohammed, et al. Current emergency and hospital medicine reports 1.2 (2013): p90 January, Craig T., et al.Circulation (2014)

  29. Argatroban • Starting dose depends on comorbid conditions: • Standard • 2mcg/kg/min • Critically Ill (Heart failure, MODS, severe anasarca, post cardiac surgery) • 1mcg/kg/min • Moderate to severe liver dysfunction (Child-Pugh Class B/C) • 0.5mcg/kg/min Presentation Title and/or Sub Brand Name Here

  30. Argatroban to WarfarinBridging to Warfarin • ≤2 mcg/kg/minute: • Stop Argatroban when INR >4 on combined warfarin + argatroban • Repeat INR in 4 to 6 hours; if INR < goal, restart argatroban • Repeat daily until desired INR on warfarin alone is obtained. • >2 mcg/kg/minute: • Decrease argatrobanto 2 mcg/kg/minute and check INR 4 to 6 hours after dose reduction; • Stop argatroban when the INR on warfarin + argatroban >4. • Repeat INR in 4 to 6 hours; if INR < goal, restart argatroban • Repeat procedure daily until desired INR on warfarin alone is obtained. Presentation Title and/or Sub Brand Name Here

  31. Bivalirudin Dosing 1. Kearon, Clive, et al. CHEST Journal 149.2 (2016): 315-352. 2. 2014 AHA/ACC 3. Robson, Richard, et al. ClinicalPharmacology & Therapeutics 71.6 (2002): 433-439.

  32. Bivalirudin Conversion to Warfarin: • Once the platelet count has recovered to at least 150 x109/L and with an overlap of at least five days. • All direct thrombin inhibitors can prolong the INR. • The mean prolongation in the INR from bivalirudin in one study was 0.4.2 • When a patient is believed to be therapeutic on warfarin (5 days), hold bivalirudin and recheck an INR once bivalirudin is cleared (generally 2-6 hours or 3-5 half-lives Presentation Title and/or Sub Brand Name Here

  33. Antithrombotic Agents in the setting of Neuraxial Procedures • Systemic Heparin • Systemic Direct Thrombin Inhibitors (Argatroban, Bivalirudin) • GBIIb/IIIa inhibitors • Thrombolytics [10 day waiting period] http://medctrpharm.ucsf.edu/system/files/documents/UCSF%20Antithrombotics%20%20Neuraxial%20Intervention%20July%202015.pdf Presentation Title and/or Sub Brand Name Here

  34. IP Adult Anticoagulation Reversal Orders (KCentra, Praxbind)

  35. Questions?

More Related